Who
Dean L. Schorno
EVP & Chief Financial Officer
Company insider
Files Form 4 as: EVP & Chief Financial Officer, Rigel Pharmaceuticals; CFO, Genomic Health.
In numbers
- Trades disclosed
- 167
- Buys
- 1
- Sells
- 33
- Bought
- $107K
- Sold
- $2.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 13 Jan 2011
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $8,814694 at $12.70 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $12K620 at $18.70 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —694 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —620 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,286 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $48K2,000 at $24.20 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $31K1,286 at $24.20 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —694 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —620 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,286 at $0.00 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $8,814694 at $12.70 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $12K620 at $18.70 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $48K2,000 at $24.20 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $31K1,286 at $24.20 | filing |
| 1 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $44K928 at $47.50 | filing |
| 1 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $44K928 at $47.50 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
News
Ascendis Pharma A/S (NASDAQ:ASND) vs. Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head ReviewRIGL · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Dean L. Schorno; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.